Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products

  • Email
  • Help

This guideline applies to human and veterinary medicines.

Current effective version

Revision 3 - Adopted guideline

Reference numberEMEA/410/01 Rev. 3
Published29/06/2011
Effective from01/07/2011
KeywordsBovine spongifrom encelophathy (BSE), transmissible spongiform encephalopathy (TSE), Creutzeldt-Jakob disease  (CJD)
DescriptionThis document provides guidance for minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. When applicable, read together with explanatory note for medicinal products for human use on the scope of the guideline and explanatory note on the gelatin for use in pharmaceuticals.


Related content for human medicines



Related content for veterinary medicines


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more